REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX™ Platform, and StratX^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx^®, AeriSeal^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.

Investor Contact

Jeremy Feffer

LifeSci Advisors

jfeffer@lifesciadvisors.com

Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025